AlpHelix’s full-length IgG yeast display platform offers unique advantage in the development of bispecific antibodies. This platform enables formation of heterodimer of heavy chains from two different antibodies and high-throughput screening for a common light chain. This approach fully exploits existing therapeutic antibodies for the development of bispecific antibody medicines:

1.Simultaneous display of two different heavy chains on the yeast surface

2.Screening of the light chain library tailored for customers;

3.Displaying a light chain library together with heterodimer of heavy chains in the full-length IgG format on yeast surface;

4.Screening for high-affinity common light chains based on fluorescence-activated cell sorting (FACS);

5.Measuring affinities of bispecific candidates.

The IgG-like bispecific antibodies that consist of common light chains and two different heavy chains, have high affinities for two different antigens while maintaining the IgG or IgG-like fold of a native IgG. These antibodies could meet the needs of drug development, including high stability, satisfying pharmacokinetics, and standardized production.